Compare BridgeBio Pharma Inc (BBIO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Lamb Weston Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Lamb Weston Holdings Inc trades at $52.79 (market cap $7.12B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LW | |
|---|---|---|
Market Cap | $16.61B | $7.12B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $66.57 |
52-Week Low | $47.29 | $38.48 |
Enterprise Value | $18.16B | $11.00B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Lamb Weston (LW) trades at $52.27, up 0.42% today, with a bullish technical outlook and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and trades at a P/E of 25.13. Recent Q2 2026 results exceeded expectations with EPS of $0.87 versus $0.626 estimated. The company maintains a solid dividend yield with a recent $0.38 per share payout announced.
The outlook is positive given operational improvements and cost savings, though international headwinds and margin pressures pose risks. Analyst consensus is a 'Hold' with a $53.86 price target, indicating modest upside. Investors should weigh strong North American growth against geopolitical and cost challenges impacting international segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
